Clinical trials: Controlled Hypertension
Hypertension
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.
- Trial name
- NCT00219154
- Testing
- aliskiren
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 1,125 people
- Sponsor
- Novartis
Pulmonary Hypertension
Safety of SonoVue on Pulmonary Hemodynamics
This is an intra-subject crossover comparative safety study to evaluate the effect of intravenous (IV) bolus injection of SonoVue on pulmonary hemodynamics.
- Trial name
- NCT01306292
- Testing
- SonoVue
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Bracco Diagnostics, Inc
Pulmonary Arterial Hypertension
Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults
This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.
- Trial name
- NCT05938946
- Testing
- L608 Inhalation Solution
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Dyspnea, Hypertension
Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF
The purpose of this study is to evaluate dyspnea improvement and other parameters of efficacy and safety in acute heart failure (AHF) patients receiving an intravenous (IV) infusion of clevidipine in comparison to standard of…
- Conditions
- Dyspnea, Hypertension, Acute Heart Failure
- Trial name
- PRONTO II (NCT04592380)
- Testing
- Stage 1: Clevidipine (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
- Where
- 9 sites in United States
- Sponsor
- The Medicines Company
Hypertension, Diabete Type 2
Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
This clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination)…
- Trial name
- NCT07552389
- Testing
- Test group, Exploratory test group, Control group 1
- Where
- South Korea
- Volunteers
- 228 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Primary Open Angle Glaucoma, Ocular Hypertension
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
This is a pilot, proof of concept study to evaluate the safety and efficacy of ALZ-1101 dosed once daily for 28 days compared to latanoprost 0.005% ophthalmic solution in patients with elevated intraocular pressure not adequately…
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure
- Trial name
- NCT01896180
- Testing
- ALZ-1101, Latanoprost
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Alleanza Pharmaceuticals, Inc.
Uncontrolled Hypertension
SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
The purpose of this study is to evaluate the safety, tolerability pharmacokinetics and pharmacodynamics of SAL0140 healthy Chinese population.
- Trial name
- NCT07051603
- Testing
- SAL0140
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Glaucoma, Open-Angle
A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT.
- Trial name
- NCT05451329
- Testing
- VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- VivaVision Biotech, Inc
Primary Open-angle Glaucoma, Ocular Hypertension
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
TJO-002 or Acitve Control was administered on primary open-angle glaucoma or ocular hypertension patients for 12 weeks. This clinical trial study has hypothesize TJO-002 administration groups are not inferior to Active control…
- Trial name
- NCT03419975
- Testing
- TJO-002, Latanoprost
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Obstructive Sleep Apnea, Hypertension
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.
- Trial name
- NCT06785454
- Testing
- Lorundrostat
- Where
- 27 sites in United States
- Volunteers
- 48 people
- Sponsor
- Mineralys Therapeutics Inc.
Hypertension
To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension
This is a prospective, multicenter, randomized sham-controlled trial to evaluate safety and efficacy of a multi-electrode radiofrequency renal denervation system (Netrod® System) in treating patients with uncontrolled essential…
- Trial name
- NCT03261375
- Testing
- Renal Artery Radiofrequency Ablation System (Generator and Catheter ), Antihypertensive Agents
- Where
- 25 sites in China
- Volunteers
- 205 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Pulmonary Arterial Hypertension
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
This was a non-confirmatory, randomized, placebo controlled, subject and investigator blinded study of QCC374 in PAH subjects. The study was planned to have 2 Parts: Part 1, an initial safety cohort with a 0.03 mg bid starting…
- Trial name
- NCT02927366
- Testing
- QCC374
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension, Pulmonary Hypertension
A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension
This trial is a study of Remodulin in patients with pulmonary arterial hypertension who have been transitioned from Flolan therapy. The study consists of Screening, Baseline and Treatment Phases.
- Trial name
- NCT00058929
- Testing
- treprostinil sodium
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- United Therapeutics
Health Services Administration, Telemedicine
The Impact of Telemonitoring in the Management of Hypertension
Rater blinded, multi-center, prospective, randomized controlled study comparing mean 24 hour systolic blood pressure of eligible hypertensive patients in the TELEMONITORIN group versus the USUAL CARE group, at 6 months after…
- Conditions
- Health Services Administration, Telemedicine, Hypertension
- Trial name
- HOROSCOPE (NCT04607239)
- Testing
- Telemonitoring, Usual Care without Telemonitoring
- Where
- Tunisia
- Volunteers
- 460 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Hypertension
Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension
The purpose of this study was to determine if nebivolol is superior to placebo for the treatment of elevated blood pressure in Black patients with mild to moderate hypertension.
- Trial name
- NCT00145236
- Testing
- Nebivolol
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Mylan Bertek Pharmaceuticals
Hypertension
A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
This study is being conducted to evaluate the safety of MK-0954A (L100/H12.5 mg) in essential hypertension participants who are uncontrolled with MK-954H (L50/H12.5 mg).
- Trial name
- NCT01307033
- Testing
- MK-0954A, MK-954H
- Volunteers
- 278 people
- Sponsor
- Organon and Co
Hypertension
A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications
The purpose of this study is to evaluate the effect of GW906 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of GW906 as add-on therapy.
- Trial name
- NCT07835984
- Testing
- GW906
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension
The purpose this study is to compare the efficacy of eplereonone and losartan in patients with mild to moderate hypertension.
- Trial name
- NCT00649311
- Testing
- eplerenone, Losartan
- Where
- 2 sites in Taiwan
- Volunteers
- 248 people
- Sponsor
- Pfizer
Pulmonary Hypertension
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
- Trial name
- NCT00091598
- Testing
- Ambrisentan
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 372 people
- Sponsor
- Gilead Sciences
Obesity
A Study of Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity
The purposes of this study are to compare the effects of Topiramate and placebo on abdominal visceral fat accumulation at 6 months and to evaluate the safety of Topiramate for up to 12 months of continued treatment in male…
- Trial name
- NCT00231608
- Testing
- topiramate
- Volunteers
- 68 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.